As an independent not-for-profit platform, Flam3D exists for all stakeholders who are active in the domain of 3D printing. We unite, represent and support companies, research institutions, governments, and stakeholders.Continue reading “Flam3D is content partner of the 4D Printing & Meta Materials Conference”
Interview with Beatriz Pereira, University of Central Lancashire, for JakajimaTV hosted by Pieter Hermans. Current healthcare follows an ‘one size fits all’ approach, and it is associated with high variations in treatment outcomes, due to the high interindividual variability.Continue reading “3D printing of modular ‘polypills’ for personalised therapy (Video Interview)”
A JakajimaTV interview hosted by Pieter Hermans with Guido Groet, Chief Strategy Officer at Luxexcel, which is the pioneer of 3D printed prescription lenses world-wide. Founded in 2009, when the world thought this was impossible.Continue reading “3D Printed prescription lenses for eyewear and smart glasses (Video Interview).”
Researchers at the University of Basel have a vision: an individually configurable robot that will revolutionize surgical procedures and provide numerous benefits for patients. They have already taken the first steps in this direction. To further implement their vision, the Werner Siemens Foundation is now extending its funding for the “Miracle” project by CHF 12 million to a total of CHF 27 million.Continue reading “Custom 3D-printed organic implants project funded with CHF 12 million”
During two weeks from 26 January 2021 till 4 February 2021, Jakajima will organise four online 3D Medical Printing Conferences under the 3D Medical Printing Series name. Each conference will cover one specific 3D Printing Medical Topic:Continue reading “SAVE THE DATE: 3D Medical Printing Series”
In the age of the Coronavirus many individuals, professionals and companies are looking into solutions in the fight against the Corona Virus / Covid-19 virus.
JakajimaTV hosted some interviews / presentations with three professionals with different backgrounds about their fight against Corona.
Watch the video’s below or subscribe to the JakajimaTV channel here.
Presentation by Alessandro Ricci, 3Dific
Presentation by Frans de Beer
Presentation by Frits Hoff, please not the special LinkedIn Group ‘local production of medical solutions fighting Corona / COVID-19′
FabRx announces launch of M3DIMAKER
FabRx Ltd., the innovative pharmaceutical biotechnology spin-out from University College London (UCL) pioneering 3D printing of pharmaceuticals, has released the first pharmaceutical 3D printer M3DIMAKER for the manufacture of personalised medicines. FabRx is thrilled to announce that their cutting edge alternating nozzle 3D printing system, which has been tested in hospitals, pharmacies and research institutes around the world, has now been launched onto the market.Continue reading “FabRx announces launch of M3DIMAKER, first pharmaceutical 3D printer for manufacturing personalised medicines”
As countries worldwide face the challenge of managing the COVID-19 pandemic / Coronavirus, Ultimaker is making its global network of 3D printing hubs, experts, and designers directly available to hospitals in need of tools and applications that are short in supply and can be quickly produced with 3Dprinting.Continue reading “Ultimaker supports the fight against Coronavirus outbreak”
Large-scale tablet production as we know it today was invented in the late 19th century. Although the machinery has, of course, become more modern, the manufacturing process has hardly changed and is still based on the compression of powders and granules.
This traditional tablet manufacturing process is very efficient for large-scale production. Yet, when active pharmaceutical ingredient (API) dosages need to be adapted – as it is the case for clinical studies or for any tablet batch production in smaller volumes – the process is both extremely time-consuming and expensive.
Merck together with EOS is currently developing a GMP-qualified solution that uses additive manufacturing (commonly known as 3D printing) technology combined with powder formulation. Laser sintering technology will simplify tablet production tremendously, leading to significant cost and time savings in clinical development.PRODUCTION OF TABLETS HAS NEVER BEEN SIMPLER, FASTER AND CHEAPER
Tablet manufacturing using additive manufacturing will be as easy as “mixing, printing, done”. The API is mixed with excipients as a powder. A laser then fuses the mixture in a powder bed into tablets layer by layer. The tablets are then coated, and it’s all done!
In addition, 3D printing allows for API formulation to be scalable while avoiding costly reformulations throughout the entire pharmaceutical development and commercial production processes.
This novel approach is being pursued at the Merck Innovation Center, which brings ideas, knowledge and people together to create new viable businesses beyond the company’s current scope. The innovation project can benefit greatly from the long-standing formulation expertise of our Healthcare business sector as well as the experience of our Life Science business with excipients. In addition, we are partnering with EOS, the world’s leading technology supplier in the field of industrial 3D printing of metals and polymers, on this project.
The goal is to establish, in a first step, a Contract Development and Manufacturing Organization offering tablet formulation development and production for clinical trials.
In addition to making tablet manufacturing simpler and reducing time and costs, we envision making it possible to mass produce tablets flexibly and sustainably in line with patient needs. Tablet production could be tailored locally to meet specific market requirements, for example. Or imagine how it could benefit children or elderly people by providing them with tablets in special shapes and colors so that they can easily recognize their medications.
The conference of 3D Medical Printing Conference covers the development of 3D Pharma Printing.
Read more about the Merck / EOS project on the website.
by Carlos Mota, MERLN – Institute for Technology-Inspired Regenerative Medicine
End-stage renal disease (ESRD) affect 10% of the world’s population. Temporary therapies such as dialysis and organ transplantation are deemed insufficient for ESRD patient treatment. Furthermore, due to donor organ shortage multiple patients die while waiting for a suitable organ. Alternative therapies are of outmost importance to circumvent these limitations, but suitable approached to investigate renal disease and regeneration are limited are still largely dependent on animal models. In vitro models with relevant physiologic mimicry and function are necessary for the development of alternative therapies and to unravel new treatment possibilities.Continue reading “Bioprinting of renal models”